Global Liver Disease Therapeutics Market Assessment, By Disease Type [Hepatitis, Non-Alcoholic Fatty Liver Disease, Autoimmune Liver Diseases, Liver Cancer, Genetic Disorders], By Therapy Type [Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Others], By Drug Class [Antiviral Agents, Biologics, Small Molecule Drugs], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies], By Region, Opportunities and Forecast, 2018-2032F

Global liver disease therapeutics market is projected to witness a CAGR of 7.11% during the forecast period 2025-2032, growing from USD 25.67 billion in 2024 to USD 44.47 billion in 2032. The liver disease therapeutics market continues to develop at a rapid rate. This development is largely attributed to the increasing incidence of liver disease including hepatitis, fatty liver and cirrhosis due to the growing rate of unhealthy diets, alcohol consumption, and obesity. Many patients are diagnosed earlier due to better screening programs increasing their access to treatment rights away. The R&D spending from pharmaceutical companies continues to increase and is in part driving growth of the market due to increased access to new, effective therapy options. The advances in diagnostics and the availability of targeted therapies that do not require invasive testing are increasing rapidly and creating new opportunities. Governments are investing in public health follow-up and awareness of liver disease which leads to early diagnosis and prevention of liver disease.

Report Attribute	Details
Base Year	2024
Forecast Period	2025-2032F
Historical Period	2018-2023
Projected Growth Rate	CAGR of 7.11% between 2024 and 2032
Revenue Forecast in 2032	USD 44.47 billion

Pharmaceutical companies are also investing more in research and development which enhances the prospect of bringing forward new effective therapies to the market. Additionally, e-pharmacies and more accessible allied health care provide better access to needed drug therapies. Overall, demand is strong, there is continued innovation, and government policies will continue to support the market. The above factors will continue to support the growth of the market.

For instance, in April 2025, Indian Union Home Minister spoke at a World Liver Day program conducted by the Institute of Liver and Biliary Sciences (ILBS) in India and noted the need for liver health recognition and programs, such as the HEALED scheme, to promote countrywide awareness. In another instance, in April 2025, Indian Union Health Minister led a Liver Health Pledge Ceremony during a health camp organized by the Ministry in collaboration with FSSAI and the Institute of Liver and Biliary Sciences, In India.

Impact of Unhealthy Lifestyles on the Rising Prevalence of Liver Diseases

Liver diseases are rising worldwide as people continue to follow poor lifestyle habits. The combination of sedentary habits and a diet that has high saturated fats and sugar is a big part of the epidemic rise of non-alcoholic fatty liver disease (NAFLD) and its potential for progression. High alcohol consumption is still one of the biggest players in the development of alcoholic liver disease and thus cirrhosis. Smoking and drug use can also worsen liver injury, which commonly leads to obesity, along with insulin resistance and metabolic syndrome, a major risk factors for chronic liver disease. With the increasing prevalence of lifestyle habits across urban populations, liver disease prevalence will continue to increase alongside lifestyle diseases. It is going to require coordinated public health action for prevention, early diagnosis, and treatment of disease.

For instance, in 2023, the National Vital Statistics System - Mortality Data (CDC WONDER) reported 28,632 deaths due to alcoholic liver disease in the United States, equating to 8.5 deaths per 100,000 population.

Technological Innovations Driving Growth in Liver Disease Therapeutics

Technological advancement is working as a catalyst on liver therapeutics market. New tools help detect liver problems earlier. Non-invasive diagnostic tools or methods are replacing painful biopsies. Imaging techniques have become more accurate and detailed or precise. It allows doctors to see liver damage clearly and quickly. Targeted drug delivery systems are improving treatment outcomes. Medications now reach the liver more effectively. This leads to better results with fewer side effects. Biotechnology is also bringing new therapies to the market. These are designed to treat the disease at its source. Digital health platforms help the doctors to monitor patients remotely. Patients can track symptoms and share the updates in real time. Artificial intelligence (AI) is now used to study disease patterns. Interference of AI is transforming the treatment and diagnosis rapidly. AI also helps doctors choose the best treatment i.e. personalized treatment. Telemedicine is expanding the treatment access to underdeveloped areas. Furthermore, the patients in remote areas can consult liver specialists. These technologies make care faster, safer, and more effective. As innovations continue, the liver disease therapeutics market is expected to grow steadily.

For instance, in May 2025, The Vall d'Hebron Institute of Oncology launched a tool called The GIST that runs on artificial intelligence and has been designed to automate the detection and monitoring of liver tumors. It aims to ultimately increase speed and accuracy in the diagnosis of liver disease.

Hepatitis Dominates the Liver Disease Therapeutics Market

Hepatitis remains the largest segment within the liver disease therapeutics market, and it is due to its high global burden and clinical relevance. Hepatitis C is called a silent epidemic, its severity pushes the infection to chronic conditions like cirrhosis, hepatic failure, or hepatocellular carcinoma. However, the advent of direct-acting antivirals (DAAs), treatment options are becoming increasingly better, creating acceptable cure rates over shorter treatment regimens, generally with better safety profiles. Awareness of screening programs and public health responses are helping in timely diagnosis and eventually timely treatment. Additionally, pharmaceutical companies have made capital investments into further drug development including fixed-dose combinations or pan-genotypic regimens that allow access to treatment and better treatment patterns. With continued efforts from health systems and the pharmaceutical industry, the Hepatitis C segment will continue to be the largest market share of the liver disease therapeutics market in the years to come.

For instance, according to the data published in the Viral Hepatitis Surveillance Report – United States, 2023 reported an estimated 69,000 acute hepatitis C infections and over 101,000 newly diagnosed chronic cases across the United States, along with more than 11,000 related deaths. In another instance, in May 2025, Gilead Sciences, Inc. presented final Phase 3 data on bulevirtide monotherapy at the EASL Congress, showing 36% of chronic hepatitis D patients maintained undetectable viral levels nearly two years after treatment.

North America Dominates the Liver Disease Therapeutics Market

North America continues to dominate the liver disease therapeutics market due to its solid healthcare infrastructure, greater presence of global pharmaceutical companies, and improved public awareness regarding liver health. Not only is the region supporting innovation in therapeutics for hepatitis, fatty liver disease, cirrhosis, and liver cancer, but it is also fostering action in treating liver disease. Supported by a strong pipeline in research and development, both the United States and Canada have a significant portfolio from all the major pharmaceutical companies including the biggest players (e.g. Pfizer, AbbVie, and Johnson & Johnson), which all have a sustained engagement in drug innovation and continuous clinical trials for liver disease. Furthermore, the existing advanced liver disease therapeutics, extensive use of established prescription, over-the-counter medications, and growing access to medication through e-pharmacy, all around the U.S. and Canada, support the liver disease therapeutics market. Additional government health policies and initiatives such as national screening programs, support the promotion of early diagnosis, case detection, and access to timely treatment for patients. The rise in demand for effective therapy options is driven by the high rate of individuals with obesity and problematic alcohol consumption, or those with liver disease because of lifestyle risk factors. Companies in North America frequently engage in mergers and acquisitions and new product launches to strengthen their market position and introduce advanced treatments.

For instance, on November 2024, Gilead Sciences, Inc. presented new research across major liver disease indications at the American Association for the Study of Liver Diseases (AASLD) 2024 meeting.

Download Free Sample Report

Impact of U.S. Tariffs on Global Liver Disease Therapeutics Market   

• Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.
• Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries.
• Companies may select to work with domestic suppliers or alternate suppliers, which affect time.
• Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.

Report Scope

“Global Liver Disease Therapeutics Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global liver disease therapeutics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecasts between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Disease Type, Therapy Type, Drug Class, Distribution Channel
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profiled	GSK plc, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A.
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global liver disease therapeutics market has been segmented into the following categories: 

• By Disease Type
  • Hepatitis
  • Non-Alcoholic Fatty Liver Disease
  • Autoimmune Liver Diseases
  • Liver Cancer
  • Genetic Disorders
• By Therapy Type
  • Antiviral Drugs
  • Immunosuppressants
  • Vaccines
  • Immunoglobulins
  • Others
• By Drug Class
  • Antiviral Agents
  • Biologics
  • Small Molecule Drugs
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Players Landscape and Outlook

The liver disease therapeutics market is experiencing considerable activity from the major pharmaceutical companies in the area with a commitment to establish their position through new products and actions in the area. This includes companies including GSK plc, AbbVie Inc., Pfizer Inc., Johnson & Johnson Services, Inc., and Novartis AG who are funding research, clinical trials, and acquisitions to new treatment option. The focus continues to evolve to targeted therapies, biologics, and advanced medicine that will treat patients with chronic liver conditions including Non-Alcoholic Steatohepatitis (NASH), cirrhosis, and liver cancer. In addition, there are many biotech companies developing new and novel solutions to the competitive landscape. Therefore, the prospects for the market are positive given the increasing patient awareness, growing regulatory pathways favoring innovation, and increasing global need and demand for effective liver disease therapy.

For instance, in July 2025, GSK plc completed the acquisition of efimosfermin, a potential best-in-class specialty medicine aimed at treating and preventing the progression of steatotic liver disease (SLD).

Key Players Operating in Global Liver Disease Therapeutics Market are:

• GSK plc
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

If you can't find what you're searching for or have any custom requirements for global liver disease therapeutics market, you may approach our team at info@marketsandata.com.